DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS

被引:42
作者
Gao, HL
Yamasaki, EF
Chan, KK
Shen, LL
Snapka, RM
机构
[1] Ohio State Univ, Dept Radiol, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
关键词
D O I
10.1124/mol.63.6.1382
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The two known antineoplastic quinoxaline topoisomerase II poisons, XK469 (NSC 697887) and CQS ( chloroquinoxaline sulfonamide, NSC 339004), were compared for DNA cleavage site specificity, using purified human topoisomerase IIalpha and human topoisomerase IIbeta. The DNA cleavage intensity pattern for topoisomerase IIalpha poisoning by CQS closely resembled that of VM-26, despite the lack of any apparent common pharmacophore. In contrast, the topoisomerase IIalpha DNA cleavage intensity patterns of XK469 and CQS were very different from one another despite the similar overall structures of the two drugs. This suggests that the differences in DNA site specificity of topoisomerase II poisoning by XK469 and CQS may be caused by differences in their geometry, side chains, or electronic structure. The topoisomerase IIbeta-mediated DNA cleavage sites of CQS and XK469 were also very different from one another, adding further support to this idea. Earlier work has demonstrated that a number of specific topoisomerase II poisons show very similar patterns of DNA cleavage with either topoisomerase IIalpha or topoisomerase IIbeta, suggesting that the topoisomerase II isozymes play only a minor role in choices of DNA cleavage sites. However, both of the quinoxaline topoisomerase II poisons in this study showed distinctly different and unique DNA cleavage intensity patterns with each topoisomerase II isozyme. This indicates that topoisomerase II isozymes can play a major role in DNA cleavage site selection for some classes of topoisomerase II poisons.
引用
收藏
页码:1382 / 1388
页数:7
相关论文
共 33 条
[1]   EXPRESSION, DOMAIN-STRUCTURE, AND ENZYMATIC-PROPERTIES OF AN ACTIVE RECOMBINANT HUMAN DNA TOPOISOMERASE II-BETA [J].
AUSTIN, CA ;
MARSH, KL ;
WASSERMAN, RA ;
WILLMORE, E ;
SAYER, PJ ;
WANG, JC ;
FISHER, LM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (26) :15739-15746
[2]   Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons [J].
Borgnetto, ME ;
Tinelli, S ;
Carminati, L ;
Capranico, G .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 285 (02) :545-554
[3]   SIMILAR SEQUENCE SPECIFICITY OF MITOXANTRONE AND VM-26 STIMULATION OF INVITRO DNA CLEAVAGE BY MAMMALIAN DNA TOPOISOMERASE-II [J].
CAPRANICO, G ;
DEISABELLA, P ;
TINELLI, S ;
BIGIONI, M ;
ZUNINO, F .
BIOCHEMISTRY, 1993, 32 (12) :3038-3046
[4]   Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners [J].
Capranico, G ;
Guano, F ;
Moro, S ;
Zagotto, G ;
Sissi, C ;
Gatto, B ;
Zunino, F ;
Menta, E ;
Palumbo, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (21) :12732-12739
[5]  
Capranico G, 1997, TRENDS PHARMACOL SCI, V18, P323
[6]   SEQUENCE-SELECTIVE TOPOISOMERASE-II INHIBITION BY ANTHRACYCLINE DERIVATIVES IN SV40 DNA - RELATIONSHIP WITH DNA-BINDING AFFINITY AND CYTOTOXICITY [J].
CAPRANICO, G ;
ZUNINO, F ;
KOHN, KW ;
POMMIER, Y .
BIOCHEMISTRY, 1990, 29 (02) :562-569
[7]   CONFORMATIONAL DRUG DETERMINANTS OF THE SEQUENCE SPECIFICITY OF DRUG-STIMULATED TOPOISOMERASE-II DNA CLEAVAGE [J].
CAPRANICO, G ;
PALUMBO, M ;
TINELLI, S ;
MABILIA, M ;
POZZAN, A ;
ZUNINO, F .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 235 (04) :1218-1230
[8]  
CAPRANICO G, 1994, J BIOL CHEM, V269, P2504
[9]   Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26 [J].
Catapano, CV ;
Carbone, GMR ;
Pisani, F ;
Qiu, J ;
Fernandes, DJ .
BIOCHEMISTRY, 1997, 36 (19) :5739-5748
[10]   DNA TOPOISOMERASES - ESSENTIAL ENZYMES AND LETHAL TARGETS [J].
CHEN, AY ;
LIU, LF .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1994, 34 :191-218